Seguridad de los bifosfonatos en el tratamiento de la osteoporosis

Abstract

Apart from bisphosphonates adverse events described in premarketing phases; case reports, pharmacovigilance studies and alerts from regulatory agencies about other adverse events not previously described have been published in the last years. The objective of our study is the description of adverse events potentially attributable to bisphosphonates in the usual clinical practice.

We describe the adverse events of two bisphosphonates (risedronate and alendronate) in a historical cohort through a revision of medical hystory.

A total of 110 patients of 63.4 years were included, 103 (93.6%) of them were women. 33 (30%) were receiving bisphosphonate treatment at the data collection time. 68 (61.8%) received risedronic acid. In 88.2% (n = 97) of our patients the reason to start a bisphosphonate treatment was primary prevention of fractures, and in 6.4% (n = 7) of patients there was a previous diagnosis of fracture. The rest of treatments were off-label. 82 (74.5%) of our patients had any adverse event potentially attributable to bisphosphonates. The most frequent adverse events were musculoskeletal pain (58.2%) and gastrointestinal effects (24.5%).

Bisphosphonates are a well tolerated therapeutic group. The adverse events incidence in our population was similar to the incidence described in literature.